EDMONTON, Alberta, March 29 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC:MSITF) is pleased to announce that it will immediately begin the procedure to obtain certification (CE status) of its VScan HIV test kit in Europe. Medical Services has agreed to a proposal from a European pharmaceutical company whereby the pharmaceutical company will pay the complete cost necessary for the Certification (CE) of the VScan HIV test kit in Europe. As part of the certification the company will look after submission of all data required by regulatory authorities, attend all necessary meetings with regulatory authorities and complete any and all other procedures required to obtain certification. Completion of the certification will give further validation of the VScan HIV test kit. Once certification has been obtained, the VScan HIV rapid test kit can be sold in 25 European countries. Market studies show that there is a need for in excess of 6 to 8 million HIV rapid test kits in Europe per year. Completion of the CE for the VScan HIV test kit should result in sales of 2 to 3 million kits per year. About VScan The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada. Medical Services International Inc. trades in the United States on the NQB pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/ . NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies. DATASOURCE: Medical Services International Inc. CONTACT: Robert Talbot of Medical Services International Inc., +1-780-430-6363 Web site: http://www.medicalservicesintl.com/ http://www.minerva-biotech.com/

Copyright